McLauchlan L, Lancaster K, Kearnes M, Mellor R, Ritter A. "It's professional but it's personal": participation, personal connection, and sustained disagreement in drug policy reform. Int J Drug Policy. 2022 Dec;110:103903. doi: 10.1016/j.drugpo.2022.103903
Gourdet C, Giombi KC, Kosa K, Wiley J, Cates S. How four U.S. states are regulating recreational marijuana edibles. Int J Drug Policy. 2017 May;43:83-90. doi: 10.1016/j.drugpo.2017.01.018.
Davis KL, Lenz C, Houghton K, Kaye JA. Clinical outcomes of crizotinib in real-world practice settings for patients with advanced ALK-positive non-small cell lung cancer. Poster presented at the Multidisciplinary Thoracic Cancers Symposium; March 2017. San Francisco, CA. [abstract] Int J Radiat Oncol Biol Phys. 2017 May 1; 98(1):238-9.
Davis KL, Lenz C, Houghton K, Kaye JA. Real-world clinical outcomes of crizotinib treatment in ALK-positive non-small cell lung cancer patients with brain metastases. Poster presented at the Multidisciplinary Thoracic Cancers Symposium; March 2017. San Francisco, CA. [abstract] Int J Radiat Oncol Biol Phys. 2017 May 1; 98(1):239.
Kosa KM, Giombi KC, Rains CB, Cates SC. Consumer use and understanding of labelling information on edible marijuana products sold for recreational use in the states of Colorado and Washington. Int J Drug Policy. 2017 May;43:57-66. doi: 10.1016/j.drugpo.2017.01.006
VanderWalde NA, Meyer AM, Deal AM, Layton JB, Liu H, Carpenter WR, Weissler MC, Hayes DN, Fleming ME, Chera BS. Effectiveness of chemoradiation for head and neck cancer in an older patient population. Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):30-7. doi: 10.1016/j.ijrobp.2014.01.053